Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger Highlights Board's Robust Strategic Review Process and Unanimous Determination that Carisma Merger Maximizes Value for Stockhol

Sesen Bio Files Investor Presentation in Connection

with Pending Carisma Therapeutics Merger

Highlights Board's Robust Strategic Review

Process and Unanimous Determination that Carisma Merger Maximizes Value for Stockholders

Urges Stockholders to Vote "FOR"

Transaction Ahead of Special Meeting of Stockholders on March 2, 2023

Mass. - (BUSINESS WIRE) - February 2, 2023 - Sesen Bio, Inc. (NASDAQ: SESN) today filed an investor presentation

highlighting its value maximizing merger with Carisma Therapeutics Inc. ("Carisma"). The presentation can be found at www.SesenBioandCarisma.com.

Highlights of the presentation include:

Based on basic outstanding shares including unvested RSUs.

Amounts reflect potential payments in the future and have not been discounted. Does not include potential proceeds from the sale of Vicineum

or the Company's other legacy assets.

3 Based on precedent dissolution and liquidation processes

and Company projections of potential liabilities and operating expenses.

Sesen Bio urges stockholders to vote today "FOR"

the value maximizing transaction with Carisma using the WHITE proxy card ahead of the March 2, 2023, Special Meeting of Stockholders.

Bio stockholders who need assistance voting or have questions regarding the Sesen Bio Special Meeting may contact Sesen Bio's proxy

solicitor, MacKenzie Partners, toll-free at 1-800-322-2885 or email at proxy@mackenziepartners.com.

SVB Securities is acting as exclusive financial advisor to Sesen Bio

for the transaction and Hogan Lovells US LLP is serving as its legal counsel.

Bio, Inc. is a late-stage clinical company focused on targeted fusion protein therapeutics for the treatment of patients with cancer.

Sesen Bio's most advanced product candidate, Vicineum , also known as VB4-845, is a locally-administered targeted fusion

protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin

A for the treatment of non-muscle invasive bladder cancer. On July 15, 2022, Sesen Bio made the strategic decision to voluntarily

pause further development of Vicineum in the US. The decision was based on a thorough reassessment of Vicineum, which included the incremental

development timeline and associated costs for an additional Phase 3 clinical trial, following Sesen Bio's discussions with the

United States Food and Drug Administration. Sesen Bio has turned its primary focus to assessing potential strategic alternatives with

the goal of maximizing stockholder value. Additionally, Sesen Bio intends to seek a partner for the further development of Vicineum.

For more information, please visit the Company's website at www.sesenbio.com.

Based on pro forma fully diluted post-close combined company shares outstanding.

5 Reflects pro forma company value including stated valuation

for Sesen Bio, Carisma, and fully diluted value of the Moderna convertible note.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans

and prospects for Sesen Bio, Inc. (Sesen Bio), CARISMA Therapeutics Inc. (Carisma) or the combined company, Sesen Bio's, Carisma's

or the combined company's strategy or future operations, and other statements containing the words "anticipate," "believe,"

"contemplate," "expect," "intend," "may," "plan," "predict," "target,"

"potential," "possible," "will," "would," "could," "should," "continue,"

and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

For example, statements concerning the proposed transaction, the concurrent financing, the contingent value rights and other matters,

including without limitation: statements relating to the satisfaction of the conditions to and consummation of the proposed transaction,

the expected timing of the consummation of the proposed transaction, the expected ownership percentages of the combined company, Sesen

Bio's and Carisma's respective businesses, the strategy of the combined company, future operations, advancement of the combined

company's product candidates and product pipeline, clinical development of the combined company's product candidates, including

expectations regarding timing of initiation and results of clinical trials of the combined company, the ability of Sesen Bio to remain

listed on the Nasdaq Stock Market, the completion of the concurrent financing, the receipt of any payments under the contingent value

rights, and the amount and timing of distributions to be made to Sesen Bio stockholders, if any, in connection with any potential dissolution

or liquidation scenario are forward-looking statements. Actual results may differ materially from those indicated by such forward-looking

statements as a result of various important factors, including without limitation: (i) the risk that the conditions to the closing

of the proposed transaction are not satisfied, including the failure to obtain stockholder approval of matters related to the proposed

transaction in a timely manner or at all; (ii) uncertainties as to the timing of the consummation of the proposed transaction and

the ability of each of Sesen Bio and Carisma to consummate the proposed transaction, including completing the concurrent financing; (iii) risks

related to Sesen Bio's ability to correctly estimate its expected net cash at closing and Sesen Bio's and Carisma's

ability to correctly estimate and manage their respective operating expenses and expenses associated with the proposed transaction; (iv) risks

related to Sesen Bio's continued listing on the Nasdaq Stock Market until closing of the proposed transaction; (v) the risk

that as a result of adjustments to the exchange ratio, Sesen Bio stockholders or Carisma stockholders could own less of the combined company

than is currently anticipated; (vi) the risk that the conditions to payment under the contingent value rights will not be met and

that the contingent value rights may otherwise never deliver any value to Sesen Bio stockholders; (vii) risks associated with the

possible failure to realize certain anticipated benefits of the proposed transaction, including with respect to future financial and operating

results; (viii) uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the combined

company upon closing and other events and unanticipated spending and costs that could reduce the combined company's cash resources;

(ix) the effect of uncertainties related to the actions of activist stockholders, which could make it more difficult to obtain the

approval of Sesen Bio stockholders with respect to the transaction related proposals and result in Sesen Bio incurring significant fees

and other expenses, including for third-party advisors; (x) the occurrence of any event, change or other circumstance or condition

that could give rise to the termination of the merger agreement, as amended; (xi) the effect of the announcement, pendency or completion

of the merger on Sesen Bio's or Carisma's business relationships, operating results and business generally; (xii) costs

related to the merger; (xiii) the outcome of any legal proceedings instituted against Sesen Bio, Carisma or any of their respective

directors or officers related to the merger agreement or the transactions contemplated thereby; (xiv) the ability of Sesen Bio or

Carisma to protect their respective intellectual property rights; (xv) competitive responses to the proposed transaction and changes

in expected or existing competition; (xvi) the success and timing of regulatory submissions and pre-clinical and clinical trials;

(xvii) regulatory requirements or developments; (xviii) changes to clinical trial designs and regulatory pathways; (xix) changes

in capital resource requirements; (xx) risks related to the inability of the combined company to obtain sufficient additional capital

to continue to advance its product candidates and its preclinical programs; (xxi) legislative, regulatory, political and economic

developments; and (xxii) other factors discussed in the "Risk Factors" section of Sesen Bio's Annual Report on

Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the Securities Exchange Commission (SEC). In addition,

the forward-looking statements included in this press release represent Sesen Bio's and Carisma's views as of the date hereof.

Sesen Bio and Carisma anticipate that subsequent events and developments will cause the respective company's views to change. However,

while Sesen Bio may elect to update these forward-looking statements at some point in the future, Sesen Bio specifically disclaims any

obligation to do so, except as required under applicable law. These forward-looking statements should not be relied upon as representing

Sesen Bio's views as of any date subsequent to the date hereof.

Important Additional Information

In connection with the proposed transaction between Carisma and Sesen

Bio, Sesen Bio filed with the SEC a registration statement on Form S-4 (as amended, the registration statement) that includes a proxy

statement of Sesen Bio and also constitutes a prospectus of Sesen Bio with respect to shares of Sesen Bio common stock to be issued in

the proposed transaction (proxy statement/prospectus). The definitive proxy statement/prospectus was first mailed to Sesen Bio stockholders

on or about January 24, 2023. Sesen Bio may also file other relevant documents regarding the proposed transaction with the SEC. INVESTORS

AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS, INCLUDING THE REGISTRATION STATEMENT, THE DEFINITIVE PROXY STATEMENT/PROSPECTUS,

AND ALL OTHER RELEVANT DOCUMENTS THAT ARE OR WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION, INCLUDING ANY

AMENDMENTS OR SUPPLEMENTS TO THESE MATERIALS, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION

AND THE PARTIES TO THE PROPOSED TRANSACTION. Investors and security holders are able to obtain the definitive proxy statement/prospectus

and other documents that are filed or will be filed by Sesen Bio with the SEC free of charge from the SEC's website at www.sec.gov

or from Sesen Bio at the SEC Filings section of www.sesenbio.com.

No Offer or Solicitation

This press release shall not constitute an offer to sell or the solicitation

of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or

sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities

shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Subject

to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, a public offer will not be made directly

or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of

the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone or internet) of interstate